` BBNX (Beta Bionics Inc) vs S&P 500 Comparison - Alpha Spread

BBNX
vs
S&P 500

Over the past 12 months, BBNX has underperformed S&P 500, delivering a return of -25% compared to the S&P 500's 9% growth.

Stocks Performance
BBNX vs S&P 500

Loading
BBNX
S&P 500
Add Stock

Performance Gap
BBNX vs S&P 500

Loading
BBNX
S&P 500
Difference
www.alphaspread.com

Performance By Year
BBNX vs S&P 500

Loading
BBNX
S&P 500
Add Stock

Competitors Performance
Beta Bionics Inc vs Peers

Beta Bionics Inc
Glance View

Market Cap
762m USD
Industry
Health Care

Beta Bionics, Inc. is a commercial-stage medical device company. The company is headquartered in Irvine, California and currently employs 279 full-time employees. The company went IPO on 2025-01-30. The firm's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The firm's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The firm is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. The company is also in the early stages of developing a bihormonal configuration of the iLet.

BBNX Intrinsic Value
8.88 USD
Overvaluation 50%
Intrinsic Value
Price
B
Back to Top